Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,816 people get PSTI articles and Market Currents by email alert.
Get email alerts on PSTI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 7, 2013)
-
-
GlobeNewswire (Apr 30, 2013)
-
-
GlobeNewswire (Apr 18, 2013)
-
-
-
GlobeNewswire (Apr 10, 2013)
-
-
-
-
GlobeNewswire (Mar 20, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Earnings Preview: Pluristem TherapeuticsVytautas Drumelis • Tue, Jun 19, 2012 -
-
-
-
-
-
There are no Transcripts on PSTI.
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 18, 2013)
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Mar 20, 2013)
-
at CNBC.com (Mar 18, 2013)
-
GlobeNewswire (Feb 21, 2013)
-
GlobeNewswire (Feb 13, 2013)
-
GlobeNewswire (Jan 30, 2013)
-
GlobeNewswire (Jan 22, 2013)
-
GlobeNewswire (Jan 15, 2013)
-
GlobeNewswire (Jan 7, 2013)
-
GlobeNewswire (Dec 27, 2012)
-
GlobeNewswire (Dec 12, 2012)
PSTI vs. ETF Alternatives
Company Description
Currently, there's no company description for PSTI.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 13, 11:02 AM Pluristem Therapeutic (PSTI +1%) ticks higher after reporting its PLX cells tested in preclinical animal models of preeclampsia effectively improved several parameters of the disease. Details of the study will be presented on May 30th at the Society for Gynecological Investigation Summit in Jerusalem. Comment! [Healthcare, On the Move]
-
Wednesday, April 24, 9:11 AM
Premarket gainers: BKI +26%. PBTH +11%. LL +7%. PSTI +5%.
Losers: VOCS -31%. UIS -20%. EW -19%. RES -13%. AWAY -9%. SCON -9%. JNPR -7%. SVU -7%. PNRA -6%. CREE -6%. Comment! [On the Move] - Thursday, April 18, 12:09 PM Pluristem Therapeutics (PSTI -1.4%) expands its presence in the orthopedic and sports medicine markets with plans to initiate a Phase I clinical trial to evaluate the safety and efficacy of the local administration of PLX cells to patients suffering from injuries to tendons. PSTI believes that its PLX-PAD cells will improve the post-operative structural and functional status of the rotator cuff. Comment! [Healthcare]
- Thursday, April 11, 11:15 AM United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells. 1 Comment [Healthcare, On the Move]
- Wednesday, March 20, 8:56 AM Pluristem Therapeutics (PSTI) says the first group of six patients have received its PLacental Expanded cells or a placebo in a Phase I/II trial to test the therapy for treating surgically induced muscle injury. None of the patients have suffered significant side effects so far. Three groups of six patients will be enrolled in the trial. Shares +2% in Tel Aviv. (PR) Comment! [Healthcare]
- Wednesday, February 20, 2:32 PM Pluristem Therapeutics (PSTI +4%) pops on reports that the FDA has granted orphan status for its PLX Cells to treat aplastic anemia. 1 Comment [Healthcare, On the Move]
- Tuesday, January 15, 8:34 AM Pluristem Therapeutics (PSTI) climbs 6.5% after the developer of placenta-derived cell therapies receives German approval to start a Phase II study of its PLX-PAD cells in patients with Intermittent Claudication (IC), a subset of Peripheral Artery Disease that is characterized by muscle pain, numbness and fatigue, especially in the calf muscle. Around 14M people suffer from IC in the U.S. 1 Comment [Healthcare, On the Move]
- Wednesday, November 21, 2012, 12:08 PM Pluristem (PSTI +2.5%) says the FDA has acknowledged that aplastic anemia is a rare disease, confirming that potential treatments for the condition are eligible for orphan drug status. However, it also has requested that PSTI provide additional information and data for further analysis before the agency can determine if PLX cells can qualify for orphan drug designation for aplastic anemia. PSTI is focusing on the use of the cells to treat systemic diseases eliminate the need to use the intravenous route. 3 Comments [Healthcare, On the Move]
-
Friday, November 9, 2012, 9:10 AM
Premarket gainers: ZIP +27%. KYAK +26%. LGF +9%. ENR +8%. PSTI +8%. IGT +7%. WCRX +6%. ISIS +5%.
Losers: GRPN -23%. MTG -15%. ARRY -12%. PGRX -12%. SPRD -10%. JCP -8%. PVR -6%. CPIX -5%. DIS -5%. 1 Comment [On the Move] - Friday, November 9, 2012, 9:04 AM Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading." 4 Comments [Healthcare, On the Move]
-
Thursday, November 8, 2012, 9:10 AM
Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move] -
Tuesday, November 6, 2012, 9:11 AM
Premarket gainers: JIVE +14%. ROSG +9%. PSTI +8%. ACAD +7%. MIPS +6%. LF +6%. CTRP +5%. VRNG +5%.
Losers: SREV -33%. Z -16%. ESRX -11%. FOSL -10%. VVUS -5%. NVO -5%. Comment! [On the Move] - Wednesday, October 17, 2012, 11:18 AM Pluristem Therapeutics (PSTI +1%) gains after saying that preclinical and in in-vitro studies using it's Placental expanded cells resulted in a reduction of fibrotic processes. The data will be presented at the 3rd Annual Meeting of the Israel Society for Placenta Research on October 18. Comment! [Healthcare]
- Thursday, September 13, 2012, 10:39 AM Pluristem Therapeutics (PSTI -13.6%) takes a hit after pricing its offering of 8M units at $4 each, a 12% discount to yesterday's close. The units each include one share of common stock and a warrant to purchase 0.35 of a share. 3 Comments [Healthcare, On the Move]
-
Thursday, September 13, 2012, 9:10 AM
Premarket gainers: EQIX +14%. VICL +13%. APRI +13%. LRN +10%. PLL +7%. CTIC +5%.
Losers: CCRT -29%. PSTI -17%. FMER -7%. USG -6%. HK -5%. 1 Comment [On the Move] - Wednesday, September 12, 2012, 4:56 PM Pluristem Therapeutics (PSTI) says it intends to offer an undisclosed sum of common stock and warrants. Jefferies is acting as sole book-running manager, with Oppenheimer acting as co-lead. The company plans to use the funds to conduct clinical trials, research and product development activities and for general corporate purposes. Shares -11.8% AH. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 2 replies
-
-
-
- View all 0 replies
-
- View all 6 replies
-
nsahbti: Cont. > I honestly don't know how to calculate the value but their patents will be used in a huge number of applications, again, about 1.5 y
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
scubastevo80: Yes - its been confirmed on the FDA website that their cells were designated orphan status for treatment of aplastic anemia
-
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
- View all 1 replies
-
jomif8301: The several pieces of negative news, and lack of new news has allowed it to spiral down. I'm still long and buying at these lower prices.
-
- View all 1 replies
-
LATEST REPLIES
-
- View all 2 replies
-
-
-
- View all 6 replies
-
nsahbti: Cont. > I honestly don't know how to calculate the value but their patents will be used in a huge number of applications, again, about 1.5 y
-
-
- View all 2 replies
-
scubastevo80: Yes - its been confirmed on the FDA website that their cells were designated orphan status for treatment of aplastic anemia
-
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
- View all 1 replies
-
jomif8301: The several pieces of negative news, and lack of new news has allowed it to spiral down. I'm still long and buying at these lower prices.
-
- View all 1 replies
-
-
- View all 10 replies
-
nsahbti: So why did they not tell the same thing to non Hebrew reading investors?
-
-
- View all 6 replies
-
-
-
Joe Springer
Here's the latest $33,000 article, we stand at $35,814.50 http://seekingalpha.com/a/kltb $PSTI $SPPI $ARNA $ACI $MNKD $IBIO $ATRS #Sandy - View all 3 replies
-
Joe Springer: Hi IV, May 25 was start, I try to limit the trades so that it is replicable, 2 month average per trade about: http://seekingalpha.com/p/e7pf
-
-
- View all 7 replies
-
-
-
The Berenstain Bulls
PSTI is on sale, imo, long. http://bit.ly/K2JxBu http://reut.rs/LoLbQk http://yhoo.it/Jfn5Xm - View all 2 replies
-
-
-
- View all 5 replies
-
-
-
Scott Matusow
Hearing that $PSTI will soon hear from FDA in regards to their filed request for Orphan Drug Status for #Aplastic anemia #DD - View all 1 replies
-
-
Scott Matusow
According to @biomedreports, they think $PSTI should be hearing good news soon on orphan drug status -- aplastic bone marrow - View all 4 replies
-
-
-
Scott Matusow
If @BioMedreports is right, I would expect a minimum move to $5 - $6 if Pivitol clinical news included, Institutions would come in. $PSTI - View all 4 replies
-
-
